profit from every SEK 100 of sales.
SEK 0SEK 100
Nolato
SEK 53.10+2.12% today
-12.2% in 1 year
1-year low SEK 46.251-year high SEK 62.80
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay SEK 18.41 for every SEK 1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Nolato sold, what it kept, and what it did with the cash.
Sales went from SEK 10.8 billion in 2022 to SEK 9.46 billion in 2025, with SEK 777 million of profit last year.
SalesProfit
Nolato handed back more cash to shareholders than it generated last year.
SEK 404M
Free cash flow 2025SEK 273M
Bought back its own shares–
Paid as dividendsSEK 404M
Cash vs. debtSEK 482M vs. SEK 1.5B
Nolato vs. similar companies
Nolato grows the slowest of these 5 and is the cheapest for its profits.
| Company | Profit from SEK 100 of sales | Sales growth a year | Price per SEK 1 of profit |
|---|---|---|---|
| Nolato | 18.4× · Fair price | ||
 Abbott Laboratories | 29.0× · Fair price | ||
 Medtronic | 27.1× · Fair price | ||
 Stryker | 37.4× · Expensive | ||
 Edwards Lifesciences | 56.7× · Expensive |
AI analysis
An AI analyst reads Nolato's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 10,774 | 9,546 | 9,664 | 9,462 | |
| 1,428 | 1,336 | 1,613 | 1,730 | |
| 838 | 660 | 897 | 983 | |
| 1,475 | 1,269 | 1,512 | 1,596 | |
| 697 | 435 | 658 | 777 | |
| 2.59 | 1.61 | 2.44 | 2.88 | |
| 13.3% | 14.0% | 16.7% | 18.3% | |
| 7.8% | 6.9% | 9.3% | 10.4% | |
| 6.5% | 4.6% | 6.8% | 8.2% |
Balance sheet
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 10,007 | 9,300 | 9,688 | 9,282 |
| Cash | 1,011 | 688 | 672 | 482 |
| Total debt | 1,934 | 1,870 | 1,527 | 1,454 |
| Total liabilities | 4,615 | 4,129 | 3,950 | 3,750 |
| 5,392 | 5,171 | 5,738 | 5,532 | |
| 269 | 269 | 269 | 269 | |
| 10.1% | 7.6% | 9.9% | 11.7% | |
| 12.9% | 8.4% | 11.5% | 14.0% |
Cash flow
| In millions of SEK | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 406 | 781 | 1,377 | 1,062 | |
| 455 | 430 | 640 | 789 | |
| -49 | 351 | 737 | 273 | |
| Dividends paid | 512 | 512 | 404 | 404 |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 18.4×
- –
- 5.11
- 2.3×
- 1.5×
- 52.4×
- 9.6×
- 1.9%
- 5.4%
- 2.8%
Profitability
- 18.3%
- 10.4%
- 8.2%
- –
- 11.7%
- 9.8%
- –
- –
- –
- –
Growth
- −4.2%
- +3.6%
- –
- –
- +0.0%
Financial health
- 0.6×
- 0.26
- –
- 22.4×
- 1.73
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 22%of 958
Top 47%of 889
Top 31%of 601
Bottom 11%of 890
Top 44%of 987
2.8%of the share price, paid each year
On $1,000 invested$28a year at today's yield, before tax
–per share
Raised–not every year
How safe it looks
52.0% of its profit
Room to growStretchedMore than it earns: 148.0%
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
45No pass
Benjamin Graham
62Pass
Philip Fisher
39No pass
Peter Lynch
18No pass
Joel Greenblatt
37No pass
Charlie Munger
36No pass
Terry Smith
21No pass
Questions about Nolato
Is Nolato a good stock to buy?
A solid business at a fair price. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Nolato AI analysis
What does Nolato do?
Nolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products in Europe, Asia, North America, and internationally. It operates through the Medical Solutions and Engineered Solutions segments. It is in Medical Devices, based in Torekov, Sweden, with 5,607 employees.
Does Nolato pay a dividend?
Yes. At today's price the dividend is 2.8% a year, about 52% of its yearly profit. In 2025 it paid out SEK 404 million in dividends.
Is Nolato stock halal?
Yes. Nolato passes our halal screen: its business is permitted and its debt is 10% of its market value, under the 30% limit. How we check
How has Nolato stock done over the past year?
Down 12.2% over the past twelve months, to SEK 53.10. It traded between SEK 46.25 and SEK 62.80 and is 15.4% below its high.
Who are Nolato's competitors?
The largest listed companies in the same industry are Abbott Laboratories, Medtronic, Stryker and Edwards Lifesciences. The peers table on this page compares their profit, growth and price with Nolato's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.